



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |           |  |
|---|-----------|--|
| <b>(51) International Patent Classification</b> <sup>6</sup> :<br><b>C12N 15/86, 7/00, 5/10</b>   | <b>A1</b> | <b>(11) International Publication Number:</b> <b>WO 99/14354</b><br><b>(43) International Publication Date:</b> 25 March 1999 (25.03.99)   |
| <b>(21) International Application Number:</b> PCT/US98/19479<br><b>(22) International Filing Date:</b> 18 September 1998 (18.09.98)<br><b>(30) Priority Data:</b><br>60/059,330 19 September 1997 (19.09.97) US<br><b>(71) Applicant (for all designated States except US):</b> THE TRUSTEES OF THE UNIVERSITY OF THE PENNSYLVANIA [US/US]; Suite 300, 3700 Market Street, Philadelphia, PA 19104-3147 (US).<br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only):</b> WILSON, James, M. [US/US]; 1350 N. Avignon Drive, Gladwyne, PA 19035 (US). XIAO, Weidong [CN/US]; Apartment P4, 155 Washington Lane, Jenkintown, PA 19046 (US).<br><b>(74) Agents:</b> KODROFF, Cathy, A. et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US).  |           | <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.</i><br><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| <b>(54) Title:</b> METHODS AND VECTOR CONSTRUCTS USEFUL FOR PRODUCTION OF RECOMBINANT AAV<br><br><b>(57) Abstract</b><br><br>Methods for efficient production of recombinant AAV employ a host cell containing a first nucleic acid molecule comprising from 5' to 3', a parvovirus P5 promoter, a spacer, an AAV <i>rep</i> sequence and an AAV <i>cap</i> gene sequence, wherein said spacer is of sufficient size to reduce expression of the <i>rep78</i> and <i>rep68</i> gene products; a second nucleic acid molecule comprising a minigene comprising a transgene flanked by AAV inverse terminal repeats (ITRs) and under the control of regulatory sequences directing expression thereof in a host cell; and helper functions essential to the replication and packaging of rAAV, which functions are not provided by the first or second nucleic acid molecules. Host cells and molecule constructs are also described. |           |  |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   |    |  | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | ML | Mali   | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MN | Mongolia                                     | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MR | Mauritania                                   | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MW | Malawi                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | MX | Mexico                                       | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NE | Niger  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NL | Netherlands                                  | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NO | Norway                                       | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | NZ | New Zealand                                  |    |                          |
| CM | Cameroon                 |    |  | PL | Poland                                       |    |                          |
| CN | China                    | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CU | Cuba                     | KZ | Kazakhstan                               | RO | Romania                                      |    |                          |
| CZ | Czech Republic           | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| DE | Germany                  | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DK | Denmark                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| EE | Estonia                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |

## METHODS AND VECTOR CONSTRUCTS USEFUL FOR PRODUCTION OF RECOMBINANT AAV

This invention was made with financial assistance from the National Institutes of Health Grant No. NIAMS P01AR/MS43648. The United States  
5 government has certain rights in this invention.

### Background of the Invention

Adeno-associated virus (AAV) is a replication-deficient parvovirus, the genome of which is about 4.6 kb in length, including 145 bp inverted terminal repeats (ITRs). Two open reading frames encode a series of *rep* and *cap* polypeptides. *Rep*  
10 polypeptides (*rep78*, *rep68*, *rep62* and *rep40*) are involved in replication, rescue and integration of the AAV genome. The *cap* proteins (VP1, VP2 and VP3) form the virion capsid. Flanking the *rep* and *cap* open reading frames at the 5' and 3' ends are the 145 bp ITRs, the first 125 bp of which are capable of forming Y- or T-shaped duplex structures. Of importance for the development of AAV vectors, the entire *rep*  
15 and *cap* domains can be excised and replaced with a therapeutic or reporter transgene [B. J. Carter, in "Handbook of Parvoviruses", ed., P. Tijsser, CRC Press, pp.155-168 (1990)]. It has been shown that the ITRs represent the minimal sequence required for replication, rescue, packaging, and integration of the AAV genome.

When this nonpathogenic human virus infects a human cell, the viral  
20 genome integrates into chromosome 19 resulting in latent infection of the cell. Production of infectious virus and replication of the virus does not occur unless the cell is coinfecting with a lytic helper virus, such as adenovirus or herpesvirus. Upon infection with a helper virus, the AAV provirus is rescued and amplified, and both AAV and helper virus are produced. The infecting parental ssDNA is expanded to  
25 duplex replicating form (RF) DNAs in a *rep* dependent manner. The rescued AAV genomes are packaged into preformed protein capsids (icosahedral symmetry approximately 20 nm in diameter) and released as infectious virions that have packaged either + or - ss DNA genomes following cell lysis.

AAV possesses unique features that make it attractive as a vector for delivering foreign DNA to cells. Various groups have studied the potential use of AAV in the treatment of disease states; however, progress towards establishing AAV as a transducing vector for gene therapy has been slow for a variety of reasons. One  
5 obstacle to the use of AAV for delivery of DNA is lack of highly efficient schemes for encapsidation of recombinant genomes and production of infectious virions [See, R. Kotin, Hum. Gene Ther., 5:793-801 (1994)].

One proposed solution involves transfecting the recombinant adeno-associated virus (rAAV) containing the transgene into host cells followed by co-  
10 infection with wild-type AAV and adenovirus. However, this method leads to unacceptably high levels of wild-type AAV. Incubation of cells with rAAV in the absence of contaminating wild-type AAV or helper adenovirus is associated with little recombinant gene expression. In the absence of *rep*, integration is inefficient and not directed to chromosome 19.

15 A widely recognized means for manufacturing transducing AAV virions entails co-transfection with two different, yet complementing plasmids. One of these contains the therapeutic or reporter transgene sandwiched between the two *cis* acting AAV ITRs. The AAV components that are needed for rescue and subsequent packaging of progeny recombinant genomes are provided in *trans* by a second plasmid  
20 encoding the viral open reading frames for *rep* and *cap* proteins. However, both *rep* and *cap* are toxic to the host cells. This toxicity has been the major source of difficulty in providing these genes in *trans* for the construction of a useful rAAV gene therapy vector.

Other methods have been proposed to enable high titer production of  
25 rAAV. For example, US Patent No. 5,658,776 refers to packaging systems and processes for packaging AAV vectors that replace the AAV P5 promoter with a heterologous promoter. Alternatively, US Patent No. 5,622,856 refers to constructs and methods for AAV vector production, which provide constructs formed by moving the homologous P5 promoter to a position 3' to the *rep* genes, and optionally flanking  
30 the *rep-cap* and repositioned P5 promoter with FRT sequences.

There remains a need in the art for additional methods permitting the efficient production of AAV and recombinant AAV viruses for use in research and therapy.

### Summary of the Invention

5                   The present invention provides novel methods, host cells, and vector constructs which permit efficient production of rAAV, by decreasing the expression of the *rep78/rep68* gene products, while leaving the expression of *rep52*, *rep40* and AAV structural proteins at a normal level.

10                   In one aspect, the invention provides a host cell containing

(a)       a first nucleic acid molecule comprising from 5' to 3', a parvovirus P5 promoter, a spacer, an AAV *rep* sequence and an AAV *cap* sequence, wherein the spacer is of sufficient size to reduce expression of the *rep78* and *rep68* gene products;

(b)       a second nucleic acid molecule comprising a minigene

15       comprising a transgene flanked by AAV inverse terminal repeats (ITRs) and under the control of regulatory sequences directing expression thereof in a host cell; and

(c)       helper functions essential to the replication and packaging of rAAV.

20                   In another aspect, the invention provides a nucleic acid molecule useful in the production of recombinant AAV comprising from 5' to 3', a homologous P5 promoter, a spacer, an AAV *rep* sequence and an AAV *cap* sequence, wherein the spacer is of sufficient size to reduce, but not eliminate, expression of the *rep78* and *rep68* gene products.

25                   In yet a further aspect, the invention provides a method for increasing the production of recombinant adeno-associated virus (rAAV) by culturing a host cell as described above, by which the *rep78/rep68* gene products are reduced in expression, and isolating from the cell lysate or cell culture, high levels of recombinant AAV capable of expressing said transgene.

Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.

#### Brief Description of the Drawings

5 Fig. 1A is a schematic illustration of a naturally occurring AAV nucleic acid sequence illustrating the P5 promoter 5' to the start site (ATG) of the *rep* and *cap* gene sequences.

Fig. 1B is a schematic illustration of a first nucleic acid sequence of the present invention showing spacer 'X' inserted between the P5 promoter and the start  
10 site of *rep* and *cap* gene sequences.

Fig. 2A is a schematic of plasmid pFG140, a commercially available (Microbix Biosystems, Inc.) plasmid containing a substantial portion of the adenovirus type 5 genome except for the E1a and E1b genes. This plasmid may be used to provide helper functions in the method of the invention.

15 Fig. 2B is a schematic of a smaller plasmid pF $\Delta$ 13, obtained by digesting pFG140 with RsrII, removing the smaller RsrII fragment and religating the plasmid. This plasmid may also be used to provide helper functions in the method of the invention.

#### Detailed Description of the Invention

20 The invention provides methods and compositions for efficiently producing high titers of rAAV. The method of this invention may be employed to produce rAAV carrying therapeutic transgenes, which are particularly useful in transferring the transgene to a host cell or tissue. These rAAV are also useful as research reagents, or as tools for the recombinant production of a transgene product  
25 *in vitro*.

#### **I. Compositions**

In one embodiment, the invention provides a host cell which contains the following components:

(a) a first nucleic acid molecule comprising from 5' to 3', a parvovirus P5 promoter, a spacer, an AAV *rep* gene sequence and an AAV *cap* gene sequence, wherein the spacer is of sufficient size to reduce expression of the *rep78* and *rep68* gene products relative to other *rep* gene products;

5 (b) a second nucleic acid molecule comprising a minigene comprising a transgene flanked by AAV inverted terminal repeats (ITRs) and under the control of regulatory sequences directing expression thereof in a host cell; and

(c) helper functions essential to the replication and packaging of rAAV.

10 A. *The First Nucleic Acid Molecule*

The key components of the first molecule are arranged in 5' to 3' order: the parvovirus P5 promoter, a spacer interposed between the promoter and the start site of the *rep* gene sequence, and the *cap* gene sequence.

The parvovirus P5 promoter used in the first nucleic acid molecule is preferably homologous to the AAV serotype which provides the *rep* gene sequences and *cap* gene sequences. Alternatively, the promoter may be a P5 promoter from another AAV type than that which provides the *rep* and *cap* sequences. The AAV P5 promoter sequences, as well as the ITR sequences employed in the second nucleic acid molecule described below, may be obtained from any known AAV, including presently identified human AAV types. Similarly, AAVs known to infect other animals may also provide the P5 promoter, *rep* and *cap* gene sequences, and ITRs employed in the constructs of this invention. The selection of the AAV to provide any of these sequences is not anticipated to limit the following invention. For example, the P5 promoter may be provided by AAV type 1, AAV type 2, AAV type 3, AAV type 4, AAV type 5, parvovirus type H1, MVM, LuIII, or from any other parvovirus or AAV serotype. A variety of AAV strains are available from the American Type Culture Collection or are available by request from a variety of commercial and institutional sources. In the following exemplary embodiments an AAV-2 is used for convenience.

The spacer is a DNA sequence interposed between the promoter and the *rep* gene ATG (start) site. The spacer may have any desired design; that is, it may be a random sequence of nucleotides, or alternatively, may encode a gene product, such as a marker gene. The spacer may contain genes which typically incorporate start/stop and polyA sites. The spacer may be a non-coding DNA sequence from a prokaryote or eukaryote, a repetitive non-coding sequence, a coding sequence without transcriptional controls or coding sequences with transcriptional controls. As illustrated below, two exemplary sources of spacer sequence are the  $\lambda$  phage ladder sequences or yeast ladder sequences, which are available commercially, e.g., from Gibco or Boehringer Mannheim, among others.

The spacer may be of any size sufficient to reduce expression of the *rep78* and *rep68* gene products, leaving the *rep52*, *rep40* and *cap* gene products to be expressed at normal levels. The length of the spacer may therefore range from about 10 bp to about 10.0 kbp. As illustrated below spacers of 100 bp to about 8.0 kbp in length were used effectively. In one experimental design, maximum expression levels of *rep78* and *rep68* were achieved with a spacer of about 500 bp in length. Desirably, to reduce the possibility of recombination, the spacer is preferably less than 2 kbp in length. However, the invention is not so limited.

The *rep* gene sequences and *cap* gene sequences are obtained from the same or a different serotype of AAV from that which supplies the P5 promoter. These sequences may be contiguous, or may be non-contiguous sequences, as desired, and may be derived from a single AAV or from different AAV sources. The AAV *rep* and *cap* sequences, as well as the P5 promoter may be obtained by conventional means (see Example 1 below). In all cases, in the first nucleic acid molecule, the P5 promoter and spacer are 5' to the *rep cap* sequences.

The first nucleic acid molecule may be in any form which transfers these components to the host cell. As one example, the first nucleic acid molecule is preferably in the form of a plasmid, which may contain other non-viral or viral sequences. However, this molecule does not contain the AAV ITRs and generally does not contain the AAV packaging sequences. As one example, the first



nucleic acid molecule described in Example 1 below contains a plasmid sequence from the commercially available Bluescript plasmid. A series of such plasmids are identified by the designation pJWX-Y, with Y indicating a different size of spacer. As another example, a plasmid may contain the key components described above, and further contain adenovirus sequences, such as map units 0-1 and 9-16 thereof as well as plasmid sequence. This plasmid is desirably constructed so that it may be stably transfected into a cell.

Alternatively, the first nucleic acid molecule may be in the form of a recombinant virus, such as an adenovirus or baculovirus. For example, the key components may be inserted as a "minigene" into the E1 region of an E1-deleted adenovirus vector. See, e.g., published PCT patent application Nos. WO96/13598; WO96/13597 and US Patent No. 5,652,224, among others.

The first nucleic acid molecule may also exist in the host cell as an episome. Still alternatively, the molecule, or at least the key components described in detail below, may be integrated into the chromosome of the host cell. The methods employed for constructing a molecule of this invention are conventional genetic engineering or recombinant engineering techniques such as those described in conventional texts. See, e.g., Sambrook et al, Molecular Cloning. A Laboratory Manual. 2d edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989). While Example 1 provides a specific illustration of the first nucleic acid molecule of this invention, using the information provided herein, one of skill in the art may select and design other suitable first nucleic acid molecules, with the choice of spacers, P5 promoters and the like, taking into consideration such factors as length, the presence of at least one set of translational start and stop signals, and optionally, the presence of polyadenylation sites.

#### *B. The Second Nucleic Acid Molecule*

The second nucleic acid molecule provides in *cis* a minigene, which is defined sequences which comprise a selected desired transgene, a promoter, and other regulatory elements necessary for expression of the transgene in a host cell, flanked by AAV inverse terminal repeats (ITRs).

The AAV sequences employed are preferably the cis-acting 5' and 3' inverted terminal repeat (ITR) sequences [See, e.g., B. J. Carter, in "Handbook of Parvoviruses", ed., P. Tijsser, CRC Press, pp.155-168 (1990)]. The ITR sequences are about 145 bp in length. Preferably, substantially the entire sequences encoding the ITRs are used in the vectors, although some degree of minor modification of these sequences is permissible for this use. The ability to modify these ITR sequences is within the skill of the art. [See, e.g., texts such as Sambrook et al, "Molecular Cloning. A Laboratory Manual.", 2d edit., Cold Spring Harbor Laboratory, New York (1989); Carter et al, cited above; and K. Fisher *et al.*, J. Virol., 70:520-532 (1996). As described above, the AAV source of such sequences is not a limitation upon this invention.

In one embodiment, the 5' and 3' AAV ITR sequences flank the selected transgene sequence and associated regulatory elements (i.e., the 5' AAV ITR is 5' of the transgene and the regulatory elements and the 3' AAV ITR is 3' of the transgene and regulatory elements). The transgene sequence of the second molecule is a nucleic acid sequence, heterologous to the AAV sequence, which encodes a polypeptide or protein of interest. The composition of the transgene sequence depends upon the use to which the resulting second molecule is to be put. For example, one type of transgene sequence includes a reporter sequence, which upon expression produces a detectable signal. Such reporter sequences include without limitation an *E. coli* beta-galactosidase (*LacZ*) cDNA, an alkaline phosphatase gene and a green fluorescent protein gene. These sequences, when associated with regulatory elements which drive their expression, provide signals detectable by conventional means, e.g., ultraviolet wavelength absorbance, visible color change, etc. For example, where the transgene is the *LacZ* gene, the presence of rAAV is detected by assays for beta-galactosidase activity.

However, desirably, the second molecule carries a non-marker gene which can be delivered to an animal via the rAAV produced by this method. A preferred type of transgene sequence is a therapeutic gene which expresses a desired gene product in a host cell. These therapeutic nucleic acid sequences typically encode

products which, upon expression, are able to correct or complement an inherited or non-inherited genetic defect or treat an epigenetic disorder or disease. However, the selected transgene may encode any product desirable for study. The selection of the transgene sequence is not a limitation of this invention.

5 In addition to the major elements identified above, the minigene of the second molecule also includes conventional regulatory elements necessary to drive expression of the transgene in a cell transfected with this vector. Thus, the minigene comprises a selected promoter which is operatively linked to the transgene and located, with the transgene, between the AAV ITR sequences. Selection of the  
10 promoter used to drive expression of the transgene is a routine matter and is not a limitation of the vector.

In a preferred embodiment, the transgene is under the control of a cytomegalovirus (CMV) immediate early promoter/enhancer [see, e.g., Boshart et al, Cell, 41:521-530 (1985)]. However, other suitable promoters may be readily  
15 selected by one of skill in the art. Useful promoters may be constitutive promoters or regulated (inducible) promoters, which will enable control of expression of the transgene product. Another suitable promoter is the Rous sarcoma virus LTR promoter/enhancer. Still other promoter/enhancer sequences may be selected by one of skill in the art.

20 The minigene also desirably contains heterologous nucleic acid sequences including sequences providing signals required for efficient polyadenylation of the transcript and introns with functional splice donor and acceptor sites. A common poly-A sequence which is employed in the exemplary vectors of this invention is that derived from the papovavirus SV-40. The poly-A sequence generally  
25 is inserted following the transgene sequences and before the 3' AAV ITR sequence. A common intron sequence is also derived from SV-40, and is referred to as the SV-40 T intron sequence. A minigene of the present invention may also contain such an intron, desirably located between the promoter/enhancer sequence and the transgene. Selection of these and other common vector elements are conventional and many such  
30 sequences are available [see, e.g., Sambrook et al, and references cited therein].

The second nucleic acid molecule carrying the AAV ITRs flanking the minigene may be in any form which transfers these components to the host cell. As described above for the first nucleic acid molecule, the second molecule may contain a plasmid backbone. For example, the second nucleic acid molecule of Example 2 is in the form of a plasmid containing other viral or non-viral sequences. The plasmid may further contain adenovirus sequences, such as map units 0-1 and 9-16.

Alternatively, the second nucleic acid molecule may be in the form of a recombinant virus which is used to infect the host cell. The second molecule may be a recombinant replication-defective adenovirus containing the transgene operatively linked to expression control sequences in the region of an adenovirus E1 deletion. Suitable Ad/AAV recombinant viruses may be produced in accordance with known techniques. See, e.g., International patent applications WO96/13598, published May 9, 1996; WO 95/23867 published Sept. 8, 1995, and WO 95/06743 published March 9, 1995, which are incorporated by reference herein.

As either a plasmid or a virus, the second nucleic acid molecule may exist in the host cell as an episome or may be integrated into the chromosome of the host cell.

The methods useful for constructing a second nucleic acid molecule of this invention are well-known to those of skill in the art and include genetic engineering, recombinant engineering, and synthetic techniques. See, e.g., Sambrook et al, cited above; and the international patent publications cited above.

### *C. Helper functions*

Helper functions essential to the replication and packaging of rAAV are also provided by or to the host cell in a variety of ways. For example, essential helper functions may be provided by the molecules (a) and (b) which contain, for example, adenovirus gene sequences, as described above. As another example, at least one of the molecules (a) or (b) may be a recombinant virus, which also supplies some or all helper functions to the cell.

Alternatively, helper functions may be provided by the host cell by virtue of sequences integrated into the chromosome of the cell. For example, the host cell may be an adenovirus or herpesvirus packaging cell, i.e., it expresses adenovirus or herpesvirus proteins useful for the production of AAV, such as HEK 293 cells and other packaging cells. In the case where the helper functions are expressed by the selected host cell, or by the host cell transfected with (a) or (b), no additional molecules are required.

However, where a packaging cell line is not used as the host cell, or the helper functions are not sufficiently present, still another source of helper functions is a third nucleic acid molecule. In one embodiment this third nucleic acid molecule is a plasmid which contains helper functions. See, for example, the "helper" plasmids of Fig. 2A and Fig. 2B, which contain adenovirus sequences in a plasmid backbone.

In another embodiment, the third molecule is a recombinant or wild-type helper virus, such as an adenovirus, baculovirus, retrovirus or herpesvirus, which provides the helper functions. Whether the optional third molecule is a plasmid or virus, it may exist in the cell as an episome. Where the helper functions are available on a separate molecule, the "host cell" may be any mammalian cell and not necessarily a packaging cell, such as HEK 293. Examples of suitable parental host cell lines include, without limitation, HeLa, A549, KB, Detroit, and WI-38 cells. These cell lines are all available from the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209. Other suitable parent cell lines may be obtained from other sources.

Examples 1-3 below illustrate useful molecules and host cells of this invention. Using the information provided herein and known techniques, one of skill in the art could readily construct a different recombinant virus (i.e., non-adenovirus) or a plasmid molecule which is capable of driving expression of the selected component in the host cell. For example, although less preferred because of their inability to infect non-dividing cells, vectors carrying the required elements of the first or second nucleic acid molecules, e.g., the P5-spacer-*rep-cap* or the ITR-

transgene-ITR sequences, may be readily constructed using e.g., retroviruses or baculoviruses. Therefore, this invention is not limited by the virus or plasmid selected for purposes of introducing the essential elements of the first nucleic acid sequence or second nucleic acid sequence or the optional third nucleic acid sequence into the host cell.

## II. Methods of the Invention

In another embodiment, the present invention provides a method for increasing the production of rAAV by decreasing the expression of the *rep78* and *rep68* gene products, keeping the expression of *rep52* and *rep40*, and the *cap* gene products at normal levels. This method includes the steps of culturing a host cell described above, which contains nucleic acid molecules (a) and (b), and helper functions (c), as described above; and isolating from the cell lysate or cell culture, a recombinant AAV capable of expressing the transgene of molecule (b).

In one embodiment of the method, a selected host cell is co-transfected with the first and second nucleic acid molecules, as described above, and then infected with a wild-type (wt) or replication defective virus, or transfected helper plasmid, to supply the helper functions. Suitable helper viruses may be readily selected by those of skill in the art and include, for example, wt Ad2, wt Ad5, and herpesviruses, as well as the replication defective adenovirus dl309. Suitable helper plasmids may also be readily selected by those of skill in the art and include, for example, the pFG140, pFΔ13, and pBHG10, which are described herein. In another embodiment, the host cell is an adenovirus packaging cell, such as HEK 293, and the first or second nucleic acid molecule is a recombinant virus, which also contains the remaining adenovirus helper functions necessary to package AAV in the presence of the essential elements provided by (b) and (c). Selection of the means by which the helper functions are provided is not a limitation on the present invention.

Suitable techniques for introducing the molecules of this invention into the host cell are known to those of skill in the art. When all molecules or vectors are

present in a cell and the cell is provided with helper functions, the rAAV is efficiently produced.

In another embodiment of the method of this invention, a packaging cell line is constructed which stably expresses the helper functions (c), or which  
5 expresses the first nucleic molecule (a). According to this aspect of the method, the cell line expressing the (c) or (a) elements can be substituted for the vector or plasmid (a) or (c) as described above. Thus, only the second molecule (i.e., the cis plasmid) described above is subsequently introduced into the cell.

Having obtained such a helper-expressing cell line, this cell line can be  
10 infected (or transfected) with the first vector (a) containing the *rep* and *cap* genes and the second vector (b) containing the minigene described above.

The methods of this invention demonstrate that the limiting step for the high yield of rAAV is not the replication of cis plasmid; but the packaging process and *rep78* and *rep68* can interfere with the packaging process directly or indirectly.

### 15      **III.                    Production of Vectors and rAAV**

Assembly of the selected DNA sequences contained within each of the molecules described above may be accomplished utilizing conventional techniques. Such techniques include cDNA cloning such as those described in texts [Sambrook et al, cited above], use of overlapping oligonucleotide sequences of the adenovirus,  
20 AAV genome combined with polymerase chain reaction, synthetic methods, and any other suitable methods which provide the desired nucleotide sequence.

Introduction of the molecules (as plasmids or viruses) into the host cell may also be accomplished using techniques known to the skilled artisan. Where appropriate, standard transfection and co-transfection techniques may be employed,  
25 e.g.,  $\text{CaPO}_4$  transfection or electroporation using the human embryonic kidney (HEK) 293 cell line (a human kidney cell line containing a functional adenovirus E1a gene which provides a transacting E1a protein). Other conventional methods employed in

this invention include homologous recombination of the viral genomes, plaquing of viruses in agar overlay, methods of measuring signal generation, and the like.

Following infection/transfection, the host cell is then cultured to enable production of the rAAV [See, e.g., F. L. Graham and L. Prevec, Methods Mol. Biol., 5 7:109-128 (1991), incorporated by reference herein]. Desirably, once the rAAV is identified, it may be recovered and purified using standard techniques.

The following examples illustrate the preferred methods of the invention. These examples are illustrative only and are not intended to limit the scope of the invention.

#### 10 Example 1 - Construction of First Nucleic Acid Molecules

##### A. *Trans Plasmids*

An exemplary first molecule of the present invention is provided as a plasmid containing the P5--spacer--AAV *rep* and *cap* genes as follows. See Figs. 1A and 1B.

15 The AAV P5 promoter was amplified from the 121 bp XbaI-BamHI fragment from plasmid *psub201*, which contains the entire AAV2 genome [R.J. Samulski et al, J. Virol., 61:3096-3101 (1987)] by PCR using two oligonucleotides:

oligo 1: TGT AGT TAA TGA TTA ACC CGC CAT GCT  
20 ACT TAT C [SEQ ID NO: 2] and oligo 2: GGC GGC TGC GCG TTC AAA CCT  
CCC GCT TCA AAA TG [SEQ ID NO: 3]. This P5 promoter sequence was subsequently cloned into plasmid pCR2.1 (Invitrogen), resulting in a new plasmid, pCR-P5. The AAV *rep* and *cap* coding region is amplified from the AAV type 2 virus by primers TATTTAAGCCCGAGTGAGCT [SEQ ID NO: 4] and  
25 TAGCATGGCGGGTTAATCATTA ACTACA [SEQ ID NO: 5] and cloned into the unique SmaI site of pBluescript (Promega). The resulting plasmid is called pBS-AAV.

The P5 promoter is then excised from pCR-P5 by digestion with BamHI and XhoI, filled in by Klenow and then cloned into the ClaI site of



plasmid pBS-AAV. The resulting plasmid, designated as P5-X, contains a unique EcoRV site between the P5 promoter and the initiation codon of *rep78*.

The helper plasmid (i.e., first nucleic acid molecule) is made by cloning the desired spacer, in this case, either the  $\lambda$  phage or yeast 100 bp ladder and 500 bp ladder sequences (Gibco; BRL) into the EcoRV site in P5-X. The resulting series of plasmids are designated as pJWX-Y (Fig. 1A). Reference to Table I codifies these plasmids as pJWX-Y, in which Y indicates the size of the plasmid. The spacer sizes present in these plasmids range from 100 bp to 8 kb. Fig. 1A represents the normal relationship of P5 to the *rep* and *cap* genes. Fig. 1B represents the P5-spacer-*rep-cap* configuration of the first nucleic molecule.

#### Example 2 - Construction of Second Nucleic Acid Molecule

A "cis" plasmid, or second nucleic acid molecule useful in the present invention contains a minigene comprising AAV ITRs flanking a promoter and transgene, the minigene inserted into a plasmid backbone. In the present example, the exemplary cis plasmid is AV.CMV*LacZ* [SEQ ID NO: 1; see International Patent Application NO. WO95/13598] was utilized as the cis plasmid (the second nucleic acid molecule) useful in the methods of this invention. It is a rAAV cassette in which AAV *rep* and *cap* genes are replaced with a minigene expressing  $\beta$ -galactosidase from a CMV promoter. The linear arrangement of pAV.CMV*LacZ* includes:

- (a) the 5' AAV ITR (bp 1-173) obtained by PCR using pAV2 [C. A. Laughlin et al, Gene, 23: 65-73 (1983)] as template [nucleotide numbers 365-538 of SEQ ID NO:1];
- (b) a CMV immediate early enhancer/promoter [Boshart et al, Cell, 41:521-530 (1985); nucleotide numbers 563-1157 of SEQ ID NO:1],
- (c) an SV40 intron (nucleotide numbers 1178-1179 of SEQ ID NO:1),
- (d) *E. coli* beta-galactosidase cDNA (nucleotide numbers 1356 - 4827 of SEQ ID NO:1),

(e) an SV40 polyadenylation signal (a 237 BamHI-BclI restriction fragment containing the cleavage/poly-A signals from both the early and late transcription units; nucleotide numbers 4839 - 5037 of SEQ ID NO:1) and

(f) 3'AAV ITR, obtained from pAV2 as a SnaBI-BglII fragment (nucleotide numbers 5053 - 5221 of SEQ ID NO:1). The remainder of the plasmid is simply plasmid backbone from a pBR322-derivative.

### Example 3 - Production of rAAV

According to one embodiment of the present invention,  $5 \times 10^6$  HEK 293 cells (American Type Culture Collection, Rockville, Maryland) were transfected as follows: 2  $\mu$ g of the helper plasmid pF $\Delta$ 13 (Fig. 2B), 1  $\mu$ g cis plasmid (pAV.CMV*LacZ* [SEQ ID NO: 1] of Example 2) and 1  $\mu$ g of a trans plasmid selected from the groups listed in Table I, were transfected into 293 cells using DOTAP (Boehringer Mannheim Biotech).

Forty-eight hours later, each group of cells were harvested [J. Price et al, Proc. Natl. Acad. Sci., USA, 84:156-160 (1987)]. The cell lysate was then subjected to three rounds of freeze-thaw cycles. The amount of rAAV virus in supernatant was then titer by x-gal assay. To get pure rAAV virus, the cell lysate can be purified by CsCl gradient.

Table I lists the identity of the first nucleic acid molecule (i.e., the trans plasmid), the size of the spacer therein, and the total yield of rAAV from  $2 \times 10^7$  cells in two production experiments was reported as *LacZ*-forming units (LFU). In Table I below 1 unit represent  $1 \times 10^5$  LFU. In this case, pAdAAV represents a helper plasmid containing no spacer between P5 and *repcap* (see Fig. 1A).

Table I

|    |                       |                   | <u>Total Yield</u> |            |             |
|----|-----------------------|-------------------|--------------------|------------|-------------|
|    | <u>pTrans plasmid</u> | <u>Spacer</u>     | <u>1st</u>         | <u>2nd</u> | <u>Avg.</u> |
| 5  | pAdAAV                | none              | 0.6                | 2.6        | 1.6         |
|    | pJWX-100              | 100 bp            | 1                  | 8.7        | 4.9         |
|    | pJWX-200              | 2x100 bp repeats  | 22                 | 33.4       | 28          |
|    | pJWX-300              | 3x100 bp repeats  | 25                 | 70         | 48          |
|    | pJWX-400              | 4x100 bp repeats  | 29                 | 60         | 45          |
| 10 | pJWX-500              | 5x100 bp repeats  | 24                 | 55         | 40          |
|    | pJWX-600              | 6x100 bp repeats  | 31                 | 130        | 81          |
|    | pJWX-700              | 7x100 bp repeats  | 26                 | 31.4       | 29          |
|    | pJWX-800              | 8x100 bp repeats  | 29                 | 28.3       | 29          |
|    | pJWX-900              | 9x100 bp repeats  | N/A                | 24         | 24          |
| 15 | pJWX-1 k              | 10x100 bp repeats | N/A                | 33         | 33          |
|    | pJWX-1.1 k            | 11x100 bp repeats | 15                 | 29         | 22          |
|    | pJWX-0.5 k            | 500 bp insert     | 30                 | 72         | 51          |
|    | pJWX-1 k              | 1 kb insert       | 25                 | 40         | 33          |
|    | pJWX-1.5 k            | 1.5 kb insert     | 16                 | 19         | 18          |
| 20 | pJWX-2 k              | 2kb insert        | 20                 | 21         | 21          |
|    | pJWX-2.5 k            | 2.5kb insert      | 19                 | 32         | 26          |
|    | pJWX-3 k              | 3.02 kb insert    | 20                 | 17         | 19          |
|    | pJWX-3.5 k            | 3.5 kb insert     | 21                 | 18.4       | 20          |
|    | pJWX-4 k              | 4.01 kb insert    | 26                 | 12.7       | 19          |
| 25 | pJWX-4.5 k            | 4.5kb insert      | 16                 | 25         | 21          |
|    | pJWX-5 k              | 5.01 kb insert    | 25                 | 13.2       | 19          |
|    | pJWX-8 k              | 8 kb insert       | 27                 | 17.4       | 22          |

Surprisingly the rAAV yield is greatly improved using these helper plasmids.

#### Example 4 - Further Characterization of the rAAV Produced by the Method

30

##### *A. Western blots*

A Western blot was performed on transfections using a variety of different trans plasmids having different spacer sequences (Example 3). The results showed that the expression of *rep78* and *rep68* from these rAAV was greatly reduced while the expression of *rep52*, *rep40* and AAV structural proteins remained unchanged. The results showed that replication of the gene containing cis plasmid

35

was not significantly affected even though the amount of *rep78* and *rep68* was decreased.

Therefore, the optimization of *rep78* and *rep68* expression is critical for high titer rAAV production.

5                    *B. Southern Blot*

A Southern blot was performed on transfections using the method of this invention using as "trans" plasmids or first nucleic acid molecules, either mock (no trans plasmid), AdAAV (a plasmid containing no spacer between the P5 and *rep* ATG site), or trans plasmids of the present invention containing varying  
10 sizes of spacer.

The position of the dimer and monomer bands did not change across all trans plasmids used. This demonstrates that the spacers between the P5 promoter and *rep* and *cap* genes of the trans plasmids of the invention do not affect the replication of the cis plasmid in the method. The AAV *rep78/68* expression is  
15 sufficient in the method of this invention to maintain normal AAV replication.

Example 5 - Titer Comparisons

The following two tables of data represent studies in which the methods of the present invention were performed by, (a) transfecting 293 cells by calcium phosphate precipitation with the trans plasmids identified in each table, the cis  
20 plasmid of Example 2 and the pF $\Delta$ 13 helper plasmid of Fig. 2A or (b) transfecting  $5 \times 10^6$  HEK 293 cells (American Type Culture Collection, Manassas, Virginia) with 1  $\mu$ g cis plasmid (pAV.CMVLacZ [SEQ ID NO: 1] of Example 2) and 1  $\mu$ g of a trans plasmid selected from the groups listed in Table III using Lipofectin (Gibco BRL). These cells were thereafter infected with wildtype adenovirus type 5 at an MOI of 5 to  
25 supply the helper functions.

Table II illustrates the virus titers of three trials using protocol (a).

TABLE II

|   | <u>Trans Plasmid</u> | <u>Trial 1</u> | <u>Trial 2</u> | <u>Trial 3</u> |
|---|----------------------|----------------|----------------|----------------|
|   | Mock (no trans)      | 0              | 0              | 0              |
|   | AdAAV (no spacer)    | 100            | 100            | 100            |
| 5 | pJWX-23              | 693            | 391            | 838            |
|   | pJWX-4k              | 344            | 330            | 444            |
|   | pJWX-1k              | 441            | 321            | 475            |
|   | pJWX-500             | 344            | 278            | 437            |

Table III illustrates the titers of one trial using protocol (b). In this  
 10 case a titer unit of 1 is equivalent to  $3 \times 10^6$  infectious particles.

TABLE III

|    | <u>Trans plasmid</u> | <u>Titer</u> |
|----|----------------------|--------------|
|    | Mock                 | 0.0          |
| 15 | AdAAV                | 0.9          |
|    | pJWX-100             | 3.4          |
|    | pJWX-200             | 2.4          |
|    | pJWX-300             | 5.4          |
|    | pJWX-400             | 3.9          |
| 20 | pJWX-500             | 7.2          |
|    | pJWX-600             | 3.6          |
|    | pJWX-700             | 2.3          |
|    | pJWX-800             | 3.0          |
|    | pJWX-900             | 3.6          |
| 25 | pJWX-1k              | 2.5          |
|    | pJWX-1.5k            | 1.0          |
|    | pJWX-2k              | 2.0          |

Publications cited in this specification are incorporated herein by  
 reference. Numerous modifications and variations of the present invention are  
 30 included in the above-identified specification and are expected to be obvious to one of  
 skill in the art. Such modifications and alterations to the processes of the present  
 invention are believed to be encompassed in the scope of the claims appended hereto.

## WHAT IS CLAIMED IS:

1. A recombinant host cell containing
  - (a) a first nucleic acid molecule comprising, from 5' to 3', a parvovirus P5 promoter, a spacer, an AAV *rep* sequence and an AAV *cap* gene sequence, wherein said spacer is of sufficient size to reduce expression of the *rep78* and *rep68* gene products relative to other *rep* gene products, and
  - (b) a second nucleic acid molecule comprising a minigene comprising a transgene flanked by AAV inverse terminal repeats (ITRs) and under the control of regulatory sequences directing expression thereof in a host cell; and
  - (c) helper functions essential to the replication and packaging of rAAV.
2. The cell according to claim 1 wherein said spacer is between about 10 bp to 10 kb in length.
3. The cell according to claim 1 wherein the spacer sequence is between 100 bp to 3.8 kb in length.
4. The cell according to claim 1 wherein said spacer sequence is about 500 bp in length.
5. The cell according to claim 1 wherein the spacer sequence is a random sequence of nucleotides.
6. The cell according to claim 1 wherein said spacer sequence encodes a gene product.
7. The cell according to claim 1 wherein said first nucleic acid molecule is a plasmid.

8. The cell according to claim 1 wherein said first nucleic acid molecule is a recombinant virus.

9. The cell according to claim 1 wherein said first nucleic acid molecule is present in said cell as an episome.

10. The cell according to claim 1 wherein said first nucleic acid molecule is integrated into the chromosome of said cell.

11. The cell according to claim 1 wherein said promoter is AAV type 2 P5 promoter.

12. The cell according to claim 1 wherein said parvovirus promoter is the P5 promoter from a strain of AAV selected from the group consisting of AAV type 1, AAV type 3, AAV type H1.

13. The cell according to claim 1 wherein said second nucleic acid molecule is a plasmid.

14. The cell according to claim 1 wherein said second nucleic acid molecule is a recombinant virus.

15. The cell according to claim 1 wherein said second nucleic acid molecule is present in said cell as an episome.

16. The cell according to claim 1 wherein said second nucleic acid molecule is integrated into the chromosome of said cell.

17. The cell according to claim 1 wherein said helper functions are provided by a third nucleic acid molecule.

18. The cell according to claim 17 wherein said third nucleic acid molecule is a plasmid.

19. The cell according to claim 17 wherein said third nucleic acid molecule is a recombinant or wild-type virus.

20. The cell according to claim 17 wherein said third nucleic acid molecule is present in said cell as an episome.

21. The cell according to claim 17 wherein said third nucleic acid molecule is integrated into the chromosome of said cell.

22. The cell according to claim 1 which is derived from a HEK 293 cell.

23. A nucleic acid molecule comprising from 5' to 3': a parvovirus P5 promoter, a spacer, an AAV *rep* gene sequence and an AAV *cap* gene sequence, wherein said spacer is of sufficient size to reduce expression of the *rep78* and *rep68* gene products relative to other *rep* gene products.

24. The molecule according to claim 23 wherein said spacer is between about 10 bp to 10 kb in length.

25. The molecule according to claim 23 wherein the spacer sequence is between 100 bp to 3.8 kb in length.

26. The molecule according to claim 23 wherein said spacer sequence is about 500 bp in length.



27. The molecule according to claim 23 wherein the spacer sequence is a random sequence of nucleotides.

28. The molecule according to claim 23 wherein said spacer sequence encodes a gene product.

29. The molecule according to claim 23 which is a plasmid.

30. The molecule according to claim 23 which is a recombinant virus.

31. The molecule according to claim 23 which is integrated into the chromosomes of a cell.

32. The molecule according to claim 23 which is present episomally in a cell.

33. A method for producing recombinant adeno-associated virus (AAV), said method comprising the steps of

(a) culturing a recombinant host cell containing

(i) a first nucleic acid molecule comprising from 5' to 3': a parvovirus P5 promoter, a spacer, an AAV *rep* gene sequence and an AAV *cap* gene sequence, wherein said spacer is of sufficient size to reduce expression of the *rep78* and *rep68* gene products relative to other *rep* gene products, and

(ii) a second nucleic acid molecule comprising a minigene comprising a transgene under the control of regulatory sequences directing expression thereof in a host cell and flanked by AAV inverse terminal repeats (ITRs);

(iii) an optional third nucleic acid molecule which provides helper functions essential to the replication and packaging of rAAV, which functions are not provided by (i) or (ii) or said host cell; and

(b) isolating from said cell or cell culture, a recombinant AAV capable of expressing said transgene.




FIG. 1A




FIG. 1B

2/2




FIG. 2B

FIG. 2A

## SEQUENCE LISTING

&lt;110&gt; Wilson, James M.

Xiao, Weidong

The Trustees of the University of Pennsylvania

<120> Methods and Vector Constructs Useful for Production of  
Recombinant AAV

&lt;130&gt; GNVPN.027CIP1PCT

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; 60/059,330

&lt;151&gt; 1997-09-19

&lt;160&gt; 5

&lt;170&gt; PatentIn Ver. 2.0

&lt;210&gt; 1

&lt;211&gt; 8509

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Recombinant  
plasmid containing Adeno-Associated Virus  
sequences, CMV promoter & lacZ gene.

&lt;400&gt; 1

```

gcccaatacg caaaccgcct ctccccgcgc gttggccgat tcattaatgc agctgcgcgc 60
tcgctcgtc actgaggccg cccgggcaaa gcccgggcgt cgggcgacct ttggtcgccc 120
ggcctcagt agcgagcgag cgcgagaga gggagtggcc aactccatca ctagggggttc 180
cttgtagtta atgattaacc cgccatgcta cttatctacg tagccattct ctagcccctg 240
caggtcgtta cataacttac ggtaaattggc ccgcctggct gaccgcccaa cgacccccgc 300
ccattgacgt caataatgac gtatgttccc atagtaacgc caataggac tttccattga 360
cgtcaatggg tggagtattt acggtaaact gccacttgg cagtacatca agtgtatcat 420
atgccaahta cgccccctat tgacgtcaat gacggtaaht ggcccgcctg gcattatgcc 480
cagtacatga cttatggga ctttctact tggcagtaca tctacgtatt agtcacgct 540
attaccatgg tgatgcggtt ttggcagtac atcaatgggc gtggatagcg gtttgactca 600
cggggatttc caagtctcca cccattgac gtcaatggga gtttgttttg gcacaaaat 660
caacgggact ttccaaaatg tcgtaacaac tccgccccat tgacgcaaht gggcggtagg 720
cgtgtacggt gggaggtcta tataagcaga gctcgtttag tgaaccgtca gatcgcttg 780
agacgccatc cacgtgttt tgacctccat agaagacacc gggaccgatc cagcctccg 840
actctagagg atccgtact cgaggaactg aaaaaccaga aagttaactg gtaagtttag 900
tctttttgct ttttatttca ggtcccggat ccggtggtgg tgcaaatcaa agaactgctc 960

```

```

ctcagtggat gttgccttta cttctaggcc tgtacggaag tgttacttct gctctaaaag 1020
ctgcggaatt gtacccgcgg ccgcaattcc cggggatcga aagagcctgc taaagcaaaa 1080
aagaagtcac catgtcgttt actttgacca acaagaacgt gattttcggt gccggtctgg 1140
gaggcattgg tctggacacc agcaaggagc tgc tcaagcg cgatcccgtc gttttacaac 1200
gtcgtgactg ggaaaaccct ggcgttacc aacttaatcg ccttgacga catccccctt 1260
tcgccagctg gcgtaatagc gaagaggccc gcaccgatcg cccttcccaa cagttgcgca 1320
gcctgaatgg cgaatggcgc tttgcctggt ttccggcacc agaagcgggt ccggaagct 1380
ggctggagtg cgatcttcct gagggcgata ctgctcgtcg cccctcaaac tggcagatgc 1440
acggttacga tgcgcccata tacaccaacg taacctatcc cattacggtc aatccgccgt 1500
ttgttcccac ggagaatccg acgggttggt actcgctcac atttaatggt gatgaaagct 1560
ggctacagga aggccagacg cgaattatct ttgatggcgt taactcggcg ttcatctgt 1620
ggtgcaacgg gcgctgggtc gggtacggcc aggacagtcg ttgccgtct gaatttgacc 1680
tgagcgcatt ttacgcgcc ggagaaaacc gcctcgcggg gatggtgctg cgttgagtg 1740
acggcagtta tctggaagat caggatatgt ggcggatgag cggcattttc cgtgacgtct 1800
cgttgctgca taaaccgact acacaaatca gcgatttcca tgttgccact cgctttaatg 1860
atgatttcag ccgcgtgta ctggaggctg aagttcagat gtgcggcgag ttgcgtgact 1920
acctacgggt aacagtttct ttatggcagg gtgaaacgca ggtcgccagc ggcaccgcgc 1980
ctttcggcgg tgaaattatc gatgagcgtg gtggttatgc cgatcgcgtc aactacgtc 2040
tgaacgtcga aaaccgaaa ctgtggagcg ccgaaatccc gaatctctat cgtgcgggtg 2100
ttgaactgca caccgccgac ggcacgctga ttgaagcaga agcctgcgat gtcggtttcc 2160
gcgaggtgcg gattgaaaat ggtctgctgc tgc tgaacgg caagccgttg ctgattcgag 2220
gcgttaaccg tcacgagcat catcctctgc atggtcaggt catggatgag cagacgatgg 2280
tgaggatat cctgctgatg aagcagaaca actttaacgc cgtgcgctgt tcgcattatc 2340
cgaaccatcc gctgtggtac acgctgtgcg accgctacgg cctgtatgtg gtggatgaag 2400
ccaatattga aaccacggc atggtgccaa tgaatcgtct gaccgatgat ccgcgtggc 2460
taccggcgat gagcgaacgc gtaacgcgaa tgggtgcagc cgatcgtaat caccgagtg 2520
tgatcatctg tgcgtgggg aatgaatcag gccacggcgc taatcacgac gcgctgtatc 2580
gctggatcaa atctgtcgat cttcccgcg cgggtgcagta tgaaggcggc ggagccgaca 2640
ccacggccac cgatattatt tgcccgatgt acgcgcgcgt ggatgaagac cagcccttcc 2700
cggctgtgcc gaaatggtcc atcaaaaaat ggctttcgct acctggagag acgcgcccgc 2760
tgatccttgc cgaatacggc cacgcgatgg gtaacagtct tggcggttcc gctaaatact 2820
ggcaggcggt tcgtcagtat ccccgtttac agggcggtt cgtctgggac tgggtggatc 2880
agtcgctgat taaatatgat gaaaacggca acccggtggtc ggcttacggc ggtgattttg 2940
gcgatacggc gaacgatcgc cagttctgta tgaacggctt ggtctttgcc gaccgcacgc 3000
cgcatccagc gctgacggaa gcaaaacacc agcagcagtt tttccagttc cgtttatccg 3060
ggcaaaccat cgaagtgacc agcgaatacc tgttccgtca tagcgataac gagctcctgc 3120
actggatggt ggcgctggat ggtaagccgc tggcaagcgg tgaagtgcct ctggatgtcg 3180
ctccacaagg taaacagttg attgaactgc ctgaactacc gcagccggag agcgcggggc 3240
aactctggct cacagtacgc gtagtgcaac cgaacgcgac cgcatggtca gaagccgggc 3300
acatcagcgc ctggcagcag tggcgtctgg cggaaaacct cagtgtgacg ctccccgccg 3360
cgtcccacgc catcccgcac ctgaccacca gcgaaatgga tttttgcatc gagctgggta 3420
ataagcgttg gcaatttaac cgccagtcag gctttcttcc acagatgtgg attggcgata 3480
aaaaacaact gctgacgccg ctgcgcgac agttcacccg tgcaccgctg gataacgaca 3540
ttggcgtaag tgaagcgacc cgcattgacc ctaacgcctg ggtcgaacgc tggaaggcgg 3600
cgggccatta ccaggccgaa gcagcggtgt tgcagtgac gccagataca cttgctgatg 3660
cgggtgctgat tacgaccgct cacgcgtggc agcatcagg gaaaacctta tttatcagcc 3720
ggaaaacctt ccgattgat ggtagtggtc aaatggcgat taccgttgat gttgaagtgg 3780
cgagcgatac accgcatccg gcgcggattg gcctgaactg ccagctggcg caggtagcag 3840

```

```

agcgggtaaa ctggctcggga ttagggccgc aagaaaacta tcccgaaccgc cttactgccg 3900
cctgttttga ccgctgggat ctgccattgt cagacatgta taccgccgtac gtcttcccga 3960
gcgaaaacgg tctgcgctgc gggacgcgcg aattgaatta tggccacac cagtggcgcg 4020
gcgacttcca gttcaacatc agccgctaca gtcaacagca actgatggaa accagccatc 4080
gccatctgct gcacgcggaa gaaggcacat ggctgaatat cgacggtttc catatgggga 4140
ttggtggcga cgactcctgg agcccgtcag tatcggcgga attacagctg agcgcgggtc 4200
gctaccatta ccagttggtc tgggtgtcaaa aataataata accgggcagg ccatgtctgc 4260
ccgtatttct cgtaaggaaa tccattatgt actattttaa aaacacaaac ttttggtatg 4320
tcggtttatt ctttttcttt tactttttta tcatgggagc ctacttcccg tttttcccga 4380
tttggtctaca tgacatcaac catatcagca aaagtgtatc ggggtattatt tttgccgcta 4440
tttctctgtt ctcgctatta ttccaaccgc tgtttgggtc gctttctgac aaactcggcc 4500
tcgactctag gcggccgcgg ggatccagac atgataagat acattgatga gtttgacaa 4560
accacaacta gaatgcagtg aaaaaatgc tttatttgtg aaatttgtga tgctattgct 4620
ttatttgtaa ccattataag ctgcaataaa caagttaaca acaacaattg cattcatttt 4680
atgtttcagg ttcaggggga ggtgtgggag gttttttcgg atcctctaga gtcgacctgc 4740
aggggctaga atggctacgt agataagtag catggcgggt taatcattaa ctacaaggaa 4800
cccctagtga tggagtggc cactccctct ctgcgcgtc gtcgctcac tgaggccggg 4860
cgaccaaagg tcgcccgcg cccgggcttt gcccgggcgg cctcagtgag cgagcgagcg 4920
cgcagctggc gtaatagcga agaggccgc accgatcgcc cttccaaca gttgcgcagc 4980
ctgaatggcg aatggaattc cagacgattg agcgtcaaaa tgtaggtatt tccatgagcg 5040
tttttctgt tgcaatggct ggcggttaata ttgttctgga tattaccagc aaggccgata 5100
gtttgagttc ttctactcag gcaagtgatg ttattactaa tcaaagaagt attgcgacaa 5160
cggttaattt gcgtgatgga cagactcttt tactcgggtg cctcactgat tataaaaaca 5220
cttctcagga ttctggcgta ccgttctgt ctaaaatccc tttaatcggc ctctgttta 5280
gctcccgtc tgattctaac gaggaagca cgttatacgt gtcgtcaaa gcaaccatag 5340
tacgcgccct gtagcggcgc attaaagcgc gcgggtgtgg tggttacgcg cagcgtgacc 5400
gctacacttg ccagcgccct agcgcgcgt cctttcgtt tcttccctc ctttctcgcc 5460
acgttcgccg gctttccccg tcaagctcta aatcgggggc tccctttagg gttccgattt 5520
agtgttttac ggcacctga ccccaaaaaa cttgattagg gtgatggttc acgtagtggg 5580
ccatcgccct gatagacggg ttttcgccct ttgacgttg agtccacgt ctttaatagt 5640
ggactcttgt tccaaactgg aacaacactc aaccctatct cgggtctattc ttttgattta 5700
taagggtatt tgccgatttc ggcctatttg ttaaaaaatg agctgattta acaaaaaattt 5760
aacgcgaatt ttaacaaaat attaacgttt acaattttaa tatttgctta tacaatcttc 5820
ctgtttttgg ggtttttctg attatcaacc ggggtacata tgattgacat gctagtttta 5880
cgattaccgt tcatcgattc tcttgtttgc tccagactct caggcaatga cctgatagcc 5940
ttttagaga cctctcaaaa atagctaccc tctccggcat gaatttatca gctagaacgg 6000
ttgaatatca tattgatggg gatttgactg tctccggcct ttctacccg tttgaatctt 6060
tacctacaca ttactcaggc attgcattta aaatatatga gggttctaaa aatttttatc 6120
cttgcggtga aataaaggct tctcccgcaa aagtattaca gggtcataat gtttttggtta 6180
caaccgattt agctttatgc tctgaggctt tattgcttaa ttttgctaat tctttgcctt 6240
gcctgtatga tttattggat gttggaattc ctgatgcggg attttctct tacgcactctg 6300
tgcggtatth cacaccgcat atgggtgact ctcagtacaa tctgctctga tgccgcagatg 6360
ttaagccagc cccgacaccc gccaacaccc gctgacgcgc cctgacgggc ttgtctgctc 6420
ccggcatccg cttacagaca agctgtgacc gtctccggga gctgcatgtg tcagagggtt 6480
tcaccgtcat caccgaaacg cgcgagacga aagggcctcg tgatacgcc atttttatag 6540
gttaatgtca tgataataat ggtttcttag acgtcagggt gcacttttctg gggaaatgtg 6600
cgcggaaccc ctatttgttt atttttctaa atacattcaa atatgtatcc gctcatgaga 6660
caataaccct gataaatgct tcaataatat tgaaaaagga agagtatgag tattcaacat 6720

```

```

ttccgtgtcg cccttattcc cttttttgcg gcattttgcc ttccgtgttt tgctcaccce 6780
gaaacgctgg tgaaagtaaa agatgctgaa gatcagttgg gtgcacgagt gggttacatc 6840
gaactggatc tcaacagcgg taagatcctt gagagttttc gccccgaaga acgttttcca 6900
atgatgagca cttttaaaagt tctgctatgt ggcgcggtat tatcccgat tgacgccggg 6960
caagagcaac tcggtcgccg catacactat tctcagaatg acttggttga gtactcacca 7020
gtcacagaaa agcatcttac ggatggcatg acagtaagag aattatgcag tgctgccata 7080
accatgagtg ataacactgc ggccaactta cttctgacaa cgatcggagg accgaaggag 7140
ctaaccgctt ttttgacaaa catgggggat catgtaactc gccttgatcg ttgggaaccg 7200
gagctgaatg aagccatacc aaacgacgag cgtgacacca cgatgcctgt agcaatggca 7260
acaacgttgc gcaaactatt aactggcgaa ctacttactc tagcttcccg gcaacaatta 7320
atagactgga tggaggcgga taaagttgca ggaccacttc tgcgctcggc ccttccggct 7380
ggctggttta ttgctgataa atctggagcc ggtgagcgtg ggtctcgcgg tatcattgca 7440
gcactggggc cagatggtaa gccctcccgt atcgtagtta tctacacgac ggggagtcag 7500
gcaactatgg atgaacgaaa tagacagatc gctgagatag gtgcctcact gattaagcat 7560
tggttaactgt cagaccaagt ttactcatat atactttaga ttgatttaaa acttcatttt 7620
taatttaaaa ggatctaggt gaagatcctt tttgataatc tcatgaccaa aatcccttaa 7680
cgtgagtttt cgttccactg agcgtcagac cccgtagaaa agatcaaagg atcttcttga 7740
gatccttttt ttctgcgctt aatctgctgc ttgcaaacia aaaaaccacc gctaccagcg 7800
gtggtttggt tgccggatca agagctacca actctttttc cgaaggtaac tggcttcagc 7860
agagcgaga taccaaatac tgtccttcta gtgtagcctg agttaggcca ccacttcaag 7920
aactctgtag caccgectac atacctcgt ctgctaacc tgttaccagt ggctgctgcc 7980
agtggcgata agtcgtgtct taccgggttg gactcaagac gatagttacc ggataaggcg 8040
cagcggtcgg gctgaacggg gggttcgtgc acacagccca gcttgagcg aacgacctac 8100
accgaactga gatacctaca gcgtgagcta tgagaaagcg ccacgcttcc cgaagggaga 8160
aaggcgga ggtatccggg aagcggcagg gtcggaacag gagagcgac gagggagctt 8220
ccagggggaa acgctggtg tctttatagt cctgtcgggt ttcgccacct ctgacttgag 8280
cgtcgatttt tgtgatgctc gtcagggggg cggagcctat ggaaaaacgc cagcaacgcg 8340
gcctttttac ggttcctggc cttttgctgg ccttttgctc acatgttctt tctcgctta 8400
tcccctgatt ctgtggataa ccgtattacc gcctttgagt gagctgatac cgctcgccgc 8460
agccgaacga ccgagcgag cgagtcagtg agcgaggaa cggaagagc 8509

```

&lt;210&gt; 2

&lt;211&gt; 34

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: PCR primer

&lt;400&gt; 2

tgtagttaat gattaaccgc ccatgctact tacc

34

&lt;210&gt; 3

&lt;211&gt; 35

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;



<223> Description of Artificial Sequence: PCR primer

<400> 3

ggcggctgcg cgttcaaacc tcccgcttca aaatg

35

<210> 4

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<400> 4

tatttaagcc cgagtgagct

20

<210> 5

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<400> 5

tagcatggcg ggttaatcat taactaca

28

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/86 C12N7/00 C12N5/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|----------|---|-----------------------|
| Y        | WO 97 06272 A (AVIGEN INC)<br>20 February 1997<br>see the whole document<br>---   | 1-33                  |
| Y        | WATSON J. D. ET AL.: "MOLECULAR BIOLOGY<br>OF THE GENE"<br>1987, THE BENJAMIN/CUMMINGS PUBLISHING<br>COMPANY, INC. XP002091111<br>see page 703, last paragraph - page 705,<br>last paragraph<br>--- | 1-33                  |
| A        | WO 96 17947 A (ALLEN JAMES M ;TARGETED<br>GENETICS CORP (US)) 13 June 1996<br>see the whole document<br>---<br>-/--   | 1-33                  |

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

26 January 1999

Date of mailing of the international search report

04/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mandl, B

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category  | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.  |
|-----------|---|------------------------|
| A         | WO 96 40955 A (GRAHAM FRANK L ;ANTON<br>MARTINA (CA); RUDNICKI MICHAEL A (CA))<br>19 December 1996<br>see page 21, line 30 - page 22, line 7<br>---   | 1-33                   |
| A         | SAMBROOK J. ET AL.: "Molecular Cloning. A<br>laboratory manual."<br>1989 , COLD SPRING HARBOUR LABORATORY<br>PRESS XP002091112<br>see page 16.5, paragraph 3 - page 16.6,<br>paragraph 3<br>--- | 1-33                   |
| P,X,<br>L | WO 98 10086 A (UNIV PENNSYLVANIA ;PHANEUF<br>DANIEL (US); WILSON JAMES M (US))<br>12 March 1998<br>L: priority<br>see the whole document<br>-----   | 1-3,<br>6-25,<br>28-33 |

| Patent document<br>cited in search report |   | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---|---------------------|----------------------------|---------------------|
| WO 9706272                                | A | 20-02-1997          | US 5622856 A               | 22-04-1997          |
|   |   |                     | CA 2228269 A               | 20-02-1997          |
|   |   |                     | EP 0842287 A               | 20-05-1998          |
| WO 9617947                                | A | 13-06-1996          | AU 4596396 A               | 26-06-1996          |
|   |   |                     | CA 2207927 A               | 13-06-1996          |
|   |   |                     | EP 0796339 A               | 24-09-1997          |
|   |   |                     | JP 10511264 T              | 04-11-1998          |
| WO 9640955                                | A | 19-12-1996          | AU 5889796 A               | 30-12-1996          |
|   |   |                     | CA 2220997 A               | 19-12-1996          |
|   |   |                     | EP 0832267 A               | 01-04-1998          |
| WO 9810086                                | A | 12-03-1998          | AU 4183097 A               | 26-03-1998          |